FineHeart Widens International IP Protection for FlowMaker®

  • New patents in the United States, China, Japan and India
  • C. 150 international patents consolidate the company's position as a pioneer in fully implantable cardiac assist devices.
  • Synchronization of the mini-pump with the heart and "100% implantable" technology: two major innovations in the treatment of advanced heart failure

BORDEAUX, France--()--FineHeart S.A., a clinical stage medical device company developing innovative devices for cardiology today announced the successful filing of six new international patents for its FlowMaker®, a fully implantable device for the treatment of patients with advanced heart failure.

These patents increase the company's solid international portfolio to 147 within 25 patent families, covering the design, production, surgical implantation of the FlowMaker®, the non-contact energy transfer, and the intelligent system for delivering therapy in synergy with each patient's cardiac rhythm. The patents bring value and protection to the FlowMaker®'s breakthrough technology that, similar to the Pacemaker, is the only cardiac assistance device capable of adapting to the patient's activity, tracking variations in heart rate, disciminating arrhythmias and permanently synchronizing with the heart's native contraction for optimum synergistic action.

3 new U.S. patents, a 3rd headline patent in China, 2 patents in India and in Japan strengthen FineHeart's international reputation, particularly in the Asian markets which are highly protective and difficult to access in terms of intellectual and industrial protection. With more than 5 million people with advanced heart failure, and an annual increase of more than one million new patients, India is a key future market for minimally invasive surgical solutions, such as those developed by FineHeart.

Arnaud Mascarell, CEO and co-founder of FineHeart declared : "These new patents consolidate our position as a leading innovator in implantable medical devices: in the United States, they reinforce the interest in our FlowMaker® for the treatment of advanced heart failure. In China, they reaffirm our growing potential in the booming medical device market. We are also very proud of our patent in Japan, where the excellence of our technology is recognised in a fast moving medical device market. In India, the full implantability of FlowMaker®represents a major breakthrough and a paradigm shift in cardiology. The technological innovations of the FlowMaker® underline our ongoing commitment to improving cardiac care for all patients worldwide."

About The FLOWMAKER®

The FlowMaker® is the first fully intraventricular, wireless flow accelerator that provides physiological support synchronized with the heart's natural contractions. It respects the natural blood flow and does not require aortic bypass surgery. It is the first miniaturized device - barely 10 cm in size - that is adjustable to patients' needs, like a pacemaker, to treat patients with varying degrees of severity. It has no external driveline as it is recharged via a wireless transcutaneous energy transfer system (TET). The device is implanted using a minimally invasive beating-heart procedure, commonly performed by cardiac surgeons, which, on average lasts 90 minutes.

Second cause of death in the world after cancer, severe heart failure is a degenerative disease that progresses to a severe form, resulting in an inability of the heart to contract effectively. Each year, 200,000 patients are not managed effectively due to lack of treatment.

About FineHeart - FineHeart

聯絡人

Media Relations
Annie-FlorenceLoyer
afloyer@newcap.fr
+33 (0) 6 88 20 35 59

FineHeart Communications
James Palmer
j.palmer@orpheonfinance.com
+33 (0) 7 60 92 77 72

聯絡人

Media Relations
Annie-FlorenceLoyer
afloyer@newcap.fr
+33 (0) 6 88 20 35 59

FineHeart Communications
James Palmer
j.palmer@orpheonfinance.com
+33 (0) 7 60 92 77 72